Navigation Links
Phase I Research of Extended-Release Topiramate Shows Less Fluctuation in Plasma Levels
Date:4/11/2011

MAPLE GROVE, Minn., April 11, 2011 /PRNewswire/ -- Upsher-Smith Laboratories today announced the presentation of data indicating that once daily administration of USL255, a proprietary extended-release (ER) formulation of the epilepsy medication topiramate, was associated with less fluctuation in topiramate plasma levels compared to immediate-release (IR) topiramate administered twice daily in healthy volunteers.

These data were presented Monday, April 11 at the American Academy of Neurology's (AAN) 2011 Annual Meeting in Honolulu, HI, and marked another milestone in Upsher-Smith's commitment to addressing unmet patient needs in epilepsy and other central nervous system diseases.

USL255 is being developed for the treatment of adults with partial-onset seizures and is the subject of a Phase III clinical trial (PREVAIL). This proprietary extended-release formulation is designed to provide convenient once-daily dosing with reduced fluctuation in topiramate plasma levels versus traditional IR dosage forms.

"Fluctuations in plasma levels with certain antiepileptic drugs have the potential to cause challenges for patients with epilepsy. There is concern that some individuals may experience increased side effects during peak concentrations, or suffer break-through seizures if plasma levels fall too low. We are excited to share this Phase I data about USL255 and its encouraging pharmacokinetic profile with clinicians at AAN," said Mark Halvorsen, Pharm.D., Senior Director, Clinical Development at Upsher-Smith.

Abstracts of the poster presentations can be found online at www.aan.com. Titles and authors are:

  • "Development and Optimization of Extended-Release Formulations of Topiramate." Authors: Lawrence J. Lambrecht, Wesley M. Todd, John A. Carrithers, Mark B. Halvorsen.
  • "Pharmacokinetic Equivalence Between Immediate-Release Topiramate and USL255 (A Novel
    '/>"/>

SOURCE Upsher-Smith Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
2. Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710
3. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
4. Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE® Vaginal Progesterone Gel Study Results
5. Jennerex and Transgene Announce Presentation of Phase 1 Data Demonstrating that JX-594 Administration Targets Tumor Vasculature
6. BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
7. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
8. Positive Phase 2 Results Reported with Boehringer Ingelheims Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients
9. Omeros Reports Outcome of Phase 3 Trials of OMS103HP
10. Conatus Pharmaceuticals Presents Results From a Phase 2 Clinical Trial of CTS-1027 in HCV Genotype 1 Null-Responders
11. Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 ResMed (NYSE: RMD ... action against Chinese medical device manufacturer BMC Medical Co., Ltd. ... that BMC,s masks listed below infringe ResMed,s patents, and entered ... masks in the United States : ... mask , Willow nasal pillows mask , iVolve ...
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... decision support to healthcare providers for behavioral health ... has secured $30 million in equity financing from ... C. Drosos , President and Chief Executive Officer. ... adoption and development of Assurex Health,s GeneSight ...
(Date:12/24/2014)... CHENGDU, China , Dec. 23, 2014 /PRNewswire/ ... a pharmaceutical company that specializes in patented biopharmaceutical, ... active pharmaceutical ingredients (API) today announced that the ... for its Good Manufacturing Practice (GMP) certificate of ... & Drug Administration,s (CFDA). The public notice period ...
Breaking Medicine Technology:ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3
... Expands Anti-Interleukin-9 Program with Second Phase 2a ... ... 1 MedImmune, Inc. today,announced that it has initiated a multi-dose, ... in adults with,mild, persistent asthma. The placebo-controlled, dose-escalation study is,designed to ...
... lower income and education still smoke more and are less likely ... ... survey by the,Washington State Department of Health shows the number of adult smokers ... Control Program in 2000, adult smoking has gone from 22.4,percent to a new ...
Cached Medicine Technology:MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma 2Adult Smoking Rate Continues Downward Trend 2
(Date:12/25/2014)... 24, 2014 (HealthDay News) -- Among early stage breast ... than half of one percent will eventually develop leukemia ... reveals. The finding comes from a review of ... and 2007, and it suggests that the risk for ... experts had previously thought. "The frequency of bone ...
(Date:12/25/2014)... New York (PRWEB) December 25, 2014 ... continue to move forward in a number of multidistrict ... of West Virginia, Bernstein Liebhard LLP reports. According to ... is scheduled to convene a Joint Status Conference in ... 10:00 a.m. Parties have been directed to submit a ...
(Date:12/25/2014)... North Carolina (PRWEB) December 25, 2014 ... North Carolina Retirement Community, recently showed their generous ... girls of the Catawba County Parenting Network- Grandparents ... the 10 children gathered around the largest Christmas ... to open presents purchased by residents of the ...
(Date:12/24/2014)... AlignLife of Wauwatosa loves helping those in the ... holiday season, AlignLife looks forward to their annual toy drive. ... Mahalko-Leonhardt, owner of AlignLife. "It brings our patients as well ... able to give kids toys for Christmas who would be ... of our patients." , The 70 toys were donated to ...
(Date:12/24/2014)... Connie Casad, MD, a well-known and respected ... 30 years of practice experience in Dallas, Texas, has ... of dietary detoxification. The second study is scheduled to ... from test patients who just completed a 21-day detoxification ... in conducting the study, Dr. Casad said, "About 10 ...
Breaking Medicine News(10 mins):Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3
... be discouraged from drinking by doctors according to researchers. In fact ... that// moderate drinking lowered their risk of heart attack. ... half to three units of alcohol every day on average demonstrated ... healthy teetotallers. One unit is a glass of wine or a ...
... Trust in Surrey is to cut nearly 170 beds and 480 ... ,A spokeswoman for the trust said: 'The trust is reducing ... it needs fewer beds.' ,Previously 43 beds have ... axed up. ,The spokeswoman added: 'Individuals have not been identified for ...
... published in American Journal of Sports Medicine claims that a ... suffering from elbow tendonitis often termed as ‘tennis elbow’ or ... alleviate the suffering. It’s not necessarily a malady afflicting just ... This ailment starts with the degeneration of the a tendon ...
... to which, patient’s views must be taken into consideration ... ,As people are becoming more aware of their disorders ... be encouraged to know more about their care is ... insisted upon by General Medical Council. ,The ...
... researchers from the Mayo Clinic in Minnesota has found that ... of sickness, right from// common cold to polio could also ... picornavirus and its ilk can cause memory loss ... show up as an apparent shortfall in cognitive abilities. ...
... to have larger, later-stage tumors that were more difficult ... Hispanic// and Caucasian women who received the same treatment ... researchers from The University of Texas M. D. Anderson ... Oct. 23 by Cancer, a peer-reviewed journal of the ...
Cached Medicine News:Health News:Race Affects African-American Survival of Breast Cancer 2Health News:Race Affects African-American Survival of Breast Cancer 3
Indications For Usage: , Thoracic surgery. , Broncho-spirometry. , Thoracoscopies. , Differential or selective lung ventilation. ...
... Double lumen ... one-lung ventilation., ... Tube is packaged ... tube-to-circuit adaptors, suction ...
The TCB Univent® allows easily collapsing one lung for thoracoscopic procedures....
... Used for endobronchial blockade ... right lung for procedures ... The set consists of ... and an Arndt Multiport ...
Medicine Products: